8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 11, 2026·SEC
Material company update
Mar 5, 2026·SEC
Tenaya Therapeutics, Inc.(TNYA)Earnings, Financials & Key Ratios
TNYA•NASDAQ
Price updated Jun 19, 2026
AboutTenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$85M+21.0%
- Net Income-$91M+18.5%
- EPS (Diluted)-0.59+55.0%
- ROE-83.84%+12.4%
TNYA Key Insights
Tenaya Therapeutics, Inc. (TNYA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Profits declining 18.7% over 5 years
- ✗Shares diluted 80.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TNYA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TNYA Price & Volume
Tenaya Therapeutics, Inc. (TNYA) stock price & volume — 10-year historical chart
Loading chart...
TNYA Growth Metrics
Tenaya Therapeutics, Inc. (TNYA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM21.52%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.48%
Return on Capital
10 Years-63.04%
5 Years-63.11%
3 Years-78.86%
Last Year-79.28%
TNYA Recent Earnings
Tenaya Therapeutics, Inc. (TNYA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.09+0.0%
$0.09
Rev
$225,000-97.0%
$8M
Q2 2026
Mar 11, 2026Metric
Actual
Est
EPS
$0.12+7.7%
$0.13
Rev
—
$3M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.12+20.0%
$0.15
Rev
—
—
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.14+30.0%
$0.20
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.09vs $0.09+0.0% | $225,000vs $8M-97.0% |
| Q2 2026 | Mar 11, 2026 | $0.12vs $0.13+7.7% | —vs $3M |
| Q4 2025 | Nov 10, 2025 | $0.12vs $0.15+20.0% | — |
| Q3 2025 | Aug 6, 2025 | $0.14vs $0.20+30.0% | — |
Based on last 12 quarters of dataView full earnings history →
TNYA Peer Comparison
Tenaya Therapeutics, Inc. (TNYA) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 |
Compare TNYA vs Peers
Tenaya Therapeutics, Inc. (TNYA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TNYA Income Statement
Tenaya Therapeutics, Inc. (TNYA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 225K |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 1.99M | 2.48M | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M | -101K |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | -1.99M▲ 0% | -2.48M▼ 24.8% | -4.03M▼ 62.1% | -8.71M▼ 116.5% | -8.69M▲ 0.3% | -8.47M▲ 2.5% | -8.44M▲ 0.4% | 326K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | 144.89% |
Gross Profit Growth % | - | -24.84% | -62.1% | -116.47% | 0.3% | 2.52% | 0.38% | - |
Operating Expenses | 27.71M | 36.43M | 68.78M | 116.91M | 122.51M | 107.48M | 84.89M | 86.18M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 4.56M | 5.33M | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M | 23.71M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 23.15M | 31.1M | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M | 62.37M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 1.03M | 0 | 0 | 0 | 0 | 0 | -8.44M | -1000K |
Operating Income | -27.71M▲ 0% | -38.91M▼ 40.4% | -72.81M▼ 87.1% | -125.62M▼ 72.5% | -131.19M▼ 4.4% | -115.95M▲ 11.6% | -93.33M▲ 19.5% | -85.86M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | -38159.11% |
Operating Income Growth % | - | -40.42% | -87.1% | -72.54% | -4.44% | 11.62% | 19.51% | - |
EBITDA | -25.72M | -36.43M | -68.78M | -116.91M | -122.51M | -107.48M | -84.89M | -78.32M |
EBITDA Margin % | - | - | - | - | - | - | - | -34808.89% |
EBITDA Growth % | - | -41.62% | -88.81% | -69.97% | -4.79% | 12.27% | 21.01% | 22.26% |
D&A (Non-Cash Add-back) | 1.99M | 2.48M | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M | 7.54M |
EBIT | -27.71M | -38.4M | -72.72M | -123.67M | -124.08M | -111.13M | -93.33M | -85.06M |
Net Interest Income | 453K | 87K | 108K | 1.95M | 7.06M | 4.74M | 2.68M | 2.84M |
Interest Income | 453K | 87K | 108K | 1.95M | 7.06M | 4.74M | 2.68M | 2.84M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.48M | 517K | 85K | 1.96M | 7.11M | 4.82M | 2.73M | 2.85M |
Pretax Income | -26.23M▲ 0% | -38.4M▼ 46.4% | -72.72M▼ 89.4% | -123.67M▼ 70.1% | -124.08M▼ 0.3% | -111.13M▲ 10.4% | -90.6M▲ 18.5% | -83M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | -36891.11% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -25.78M▲ 0% | -38.4M▼ 48.9% | -72.72M▼ 89.4% | -123.67M▼ 70.1% | -124.08M▼ 0.3% | -111.13M▲ 10.4% | -90.6M▲ 18.5% | -83M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | -36891.11% |
Net Income Growth % | - | -48.94% | -89.4% | -70.05% | -0.34% | 10.44% | 18.48% | 21.52% |
Net Income (Continuing) | -26.23M | -38.4M | -72.72M | -123.67M | -124.08M | -111.13M | -90.6M | -83M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.95▲ 0% | -0.93▲ 2.1% | -1.69▼ 81.7% | -2.76▼ 63.3% | -1.68▲ 39.1% | -1.31▲ 22.0% | -0.59▲ 55.0% | -0.54▲ 0% |
EPS Growth % | - | 2.11% | -81.72% | -63.31% | 39.13% | 22.02% | 54.96% | 59.48% |
EPS (Basic) | -0.95 | -0.93 | -1.69 | -2.76 | -1.68 | -1.31 | -0.59 | - |
Diluted Shares Outstanding | 27.2M | 41.12M | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M | 152.97M |
Basic Shares Outstanding | 27.2M | 41.12M | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M | 152.97M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
TNYA Balance Sheet
Tenaya Therapeutics, Inc. (TNYA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 27.74M | 129.96M | 255.36M | 193.75M | 111.58M | 67.38M | 105.59M | 96.56M |
Cash & Short-Term Investments | 26.63M | 128.53M | 251.3M | 186.53M | 104.64M | 61.45M | 100.55M | 80.89M |
Cash Only | 23.87M | 128.53M | 38.13M | 95.27M | 45.68M | 4.32M | 100.55M | 80.89M |
Short-Term Investments | 2.75M | 0 | 213.17M | 91.25M | 58.96M | 57.12M | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 2.25M | 0 | 0 | 0 | 10.63M |
Days Sales Outstanding | - | - | - | - | - | - | - | 4.31K |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 4.06M | 938K | 1.16M | 842K | 5.04M | 5.05M |
Total Non-Current Assets | 10.26M | 18.2M | 61.29M | 85.19M | 58.93M | 52.56M | 41.34M | 38.51M |
Property, Plant & Equipment | 9.57M | 17.18M | 54.7M | 62.7M | 53.26M | 47.75M | 37.09M | 34.72M |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.01x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 485K | 0 | 547K | 17.7M | 0 | 0 | 419K | 838K |
Other Non-Current Assets | 199K | 1.01M | 3.58M | 4.79M | 5.68M | 4.82M | 3.83M | 3.79M |
Total Assets | 38M▲ 0% | 148.16M▲ 289.9% | 316.65M▲ 113.7% | 278.94M▼ 11.9% | 170.51M▼ 38.9% | 119.94M▼ 29.7% | 146.92M▲ 22.5% | 135.07M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 289.89% | 113.72% | -11.91% | -38.87% | -29.66% | 22.5% | -34.15% |
Total Current Liabilities | 4.12M | 5.04M | 21.77M | 24.25M | 22.73M | 15.97M | 15.44M | 16.78M |
Accounts Payable | 600K | 1.02M | 10.72M | 9.58M | 5.63M | 5.16M | 3.58M | 1.91M |
Days Payables Outstanding | 110.11 | 149.5 | 972.21 | 401.24 | 236.55 | 222.5 | 154.94 | -10.51K |
Short-Term Debt | 0 | 0 | 1.99M | 0 | 0 | 2.78M | 3.02M | 3.12M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.94M | 1.22M | 5.39M | 6.97M | 9.27M | 5.81M | 8.56M | 11.75M |
Current Ratio | 6.73x | 25.78x | 11.73x | 7.99x | 4.91x | 4.22x | 6.84x | 5.75x |
Quick Ratio | 6.73x | 25.78x | 11.73x | 7.99x | 4.91x | 4.22x | 6.84x | 5.75x |
Cash Conversion Cycle | - | - | - | - | - | - | - | 14.82K |
Total Non-Current Liabilities | 77.62M | 3.68M | 16.35M | 11.32M | 8.36M | 11.11M | 8.22M | 12.1M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 7.81M | 7M |
Capital Lease Obligations | 0 | 0 | 13.71M | 11.09M | 8.11M | 10.83M | 0 | 25.79M |
Deferred Tax Liabilities | 0 | 0 | 2.46M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 77.62M | 3.68M | 182K | 228K | 253K | 281K | 410K | 5.1M |
Total Liabilities | 81.74M | 8.72M | 38.12M | 35.57M | 31.09M | 27.09M | 23.66M | 28.88M |
Total Debt | 0 | 0 | 15.7M | 15.1M | 12.42M | 13.61M | 10.83M | 10.12M |
Net Debt | -23.87M | -128.53M | -22.43M | -80.17M | -33.26M | 9.29M | -89.72M | -70.77M |
Debt / Equity | - | - | 0.06x | 0.06x | 0.09x | 0.15x | 0.09x | 0.10x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.13x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.90x |
Interest Coverage | - | - | - | - | - | - | - | - |
Total Equity | -43.74M▲ 0% | 139.44M▲ 418.8% | 278.53M▲ 99.7% | 243.38M▼ 12.6% | 139.42M▼ 42.7% | 92.85M▼ 33.4% | 123.27M▲ 32.8% | 106.19M▲ 0% |
Equity Growth % | - | 418.8% | 99.75% | -12.62% | -42.71% | -33.4% | 32.75% | -30.22% |
Book Value per Share | -1.61 | 3.39 | 6.75 | 5.43 | 1.89 | 1.09 | 0.81 | 0.69 |
Total Shareholders' Equity | -43.74M | 139.44M | 278.53M | 243.38M | 139.42M | 92.85M | 123.27M | 106.19M |
Common Stock | 1K | 0 | 4K | 7K | 7K | 8K | 21K | 21K |
Retained Earnings | -44.42M | -82.81M | -155.53M | -279.2M | -403.28M | -514.41M | -605.01M | -624.28M |
Treasury Stock | 12.96K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -74.04K | -87K | -141K | -378K | -106K | 28K | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNYA Cash Flow Statement
Tenaya Therapeutics, Inc. (TNYA) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -24.1M | -35.45M | -60.81M | -104.42M | -102.07M | -90.5M | -68.26M | -64.39M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -47.11% | -71.56% | -71.72% | 2.25% | 11.34% | 24.57% | 96.22% |
Net Income | -26.23M | -38.4M | -72.72M | -123.67M | -124.08M | -111.13M | -90.6M | -83M |
Depreciation & Amortization | 1.99M | 2.48M | 2.96M | 6.47M | 8.69M | 8.47M | 8.85M | 7.81M |
Stock-Based Compensation | 414K | 741K | 2.95M | 11.47M | 15.31M | 16.5M | 13.05M | 9.31M |
Deferred Taxes | -82K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 64K | -42K | 1.26M | 2.16M | 3.66M | 3.59M | 2.9M | 5.1M |
Working Capital Changes | -250K | -234K | 4.74M | -849K | -5.65M | -7.93M | -2.46M | -3.6M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -10.63M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 397K | 142K | 8.6M | 1.66M | -3.28M | -581K | -1.43M | -2.51M |
Cash from Investing | -5.58M | -7.01M | -238.56M | 83.65M | 48.72M | 1.13M | 56.08M | 33.77M |
Capital Expenditures | -2.93M | -9.76M | -25.12M | -20.63M | -1.24M | -1.02M | -618K | -246K |
CapEx % of Revenue | - | - | - | - | - | - | - | 109.33% |
Acquisitions | 2.66K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | -2.66K | 0 | 0 | 8K | -25K | 17K | 0 | 0 |
Cash from Financing | 30.51M | 147.27M | 208.97M | 77.77M | 4.05M | 47.75M | 108.41M | 57.73M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 30.44M | 147.23M | 208.51M | 77.39M | 3.87M | 46.76M | 108.41M | 58.15M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -3K | -1K | -13K | 0 | 0 | 0 | 0 | 0 |
Other Financing | 68K | 34K | 461K | 380K | 181K | 987K | 0 | -415K |
Net Change in Cash | 832K▲ 0% | 104.81M▲ 12497.5% | -90.41M▼ 186.3% | 56.99M▲ 163.0% | -49.31M▼ 186.5% | -41.62M▲ 15.6% | 96.22M▲ 331.2% | 27.11M▲ 0% |
Free Cash Flow | -27.02M▲ 0% | -45.21M▼ 67.3% | -85.93M▼ 90.1% | -125.05M▼ 45.5% | -103.31M▲ 17.4% | -91.53M▲ 11.4% | -68.88M▲ 24.7% | -64.63M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | -28725.33% |
FCF Growth % | - | -67.31% | -90.08% | -45.52% | 17.39% | 11.41% | 24.74% | 24.67% |
FCF per Share | -0.99 | -1.10 | -2.08 | -2.79 | -1.40 | -1.08 | -0.45 | -0.42 |
FCF Conversion (FCF/Net Income) | 0.93x | 0.92x | 0.84x | 0.84x | 0.82x | 0.81x | 0.75x | 0.78x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNYA Key Ratios
Tenaya Therapeutics, Inc. (TNYA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -80.24% | -34.8% | -47.39% | -64.83% | -95.69% | -83.84% | -80.56% |
Return on Invested Capital (ROIC) | - | -40.9% | -44.94% | -73.06% | -83.49% | -103.18% | -164.67% |
Gross Margin | - | - | - | - | - | - | 144.89% |
Net Margin | - | - | - | - | - | - | -36891.11% |
Debt / Equity | - | 0.06x | 0.06x | 0.09x | 0.15x | 0.09x | 0.10x |
FCF Conversion | 0.92x | 0.84x | 0.84x | 0.82x | 0.81x | 0.75x | 0.78x |
Related:TNYA Dividend History·TNYA Revenue History·TNYA Price History·TNYA P/E History·TNYA Financial Ratios·TNYA Institutional Holders
TNYA SEC Filings & Documents
Tenaya Therapeutics, Inc. (TNYA) SEC filings — annual & quarterly reports (10-K, 10-Q)
TNYA Frequently Asked Questions
Tenaya Therapeutics, Inc. (TNYA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tenaya Therapeutics, Inc. (TNYA) reported $0.2M in revenue for fiscal year 2025.
Tenaya Therapeutics, Inc. (TNYA) grew revenue by 0.0% over the past year. Growth has been modest.
Tenaya Therapeutics, Inc. (TNYA) reported a net loss of $83.0M for fiscal year 2025.
Dividend & Returns
Tenaya Therapeutics, Inc. (TNYA) has a return on equity (ROE) of -83.8%. Negative ROE indicates the company is unprofitable.
Tenaya Therapeutics, Inc. (TNYA) had negative free cash flow of $64.6M in fiscal year 2025, likely due to heavy capital investments.